Literature DB >> 19258936

Frequency of pelvic lymph node metastases and parametrial involvement in stage IA2 cervical cancer: a population-based study and literature review.

Hannah van Meurs1, Otto Visser, Marrije R Buist, Fibo J W Ten Kate, Jacobus van der Velden.   

Abstract

UNLABELLED: The frequency of lymph node metastases in stage IA2 cervical cancer is reported to range from 0% to 9.7%. Treatment recommendations vary likewise from a cone biopsy to a Wertheim radical hysterectomy and pelvic lymph node dissection. The objective of this study was to get insight into the true frequency of lymph node metastases and/or parametrial involvement in stage IA2 cervical cancer.
METHODS: : The hospital records of 48 patients with stage IA2 cervical carcinoma who registered from 1994 to 2006 were reviewed, and a literature search was performed.
RESULTS: : Of 48 registered patients, 14 were confirmed to have stage IA2. No lymph node metastases or parametrial invasion and recurrences were found. The collated literature data showed a risk of lymph node metastases of 4.8% (range, 0%-9.7%). The presence of adenocarcinoma and the absence of lymph vascular space invasion resulted in a low risk on lymph node metastases (0.3% and 1.3%, respectively). Parametrial involvement has not been reported.
CONCLUSIONS: : The risk of the selected patients with stage IA2 cervical cancer on lymph node metastases is low. In patients with stage IA2 squamous cell cancer with lymph vascular space invasion, a standard pelvic lymph node dissection should be recommended. Parametrectomy should be included if the nodes are positive. In the other patients, the treatment can be individualized and does not have to include lymph node dissection or parametrectomy.

Entities:  

Mesh:

Year:  2009        PMID: 19258936     DOI: 10.1111/IGC.0b013e318197f3ef

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

Review 1.  Progress in the Study of Lymph Node Metastasis in Early-stage Cervical Cancer.

Authors:  Bang-Xing Huang; Fang Fang
Journal:  Curr Med Sci       Date:  2018-08-20

2.  The Effect of Neoadjuvant Chemotherapy on Lymph Node Metastasis of FIGO Stage IB1-IIB Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Bingxin Chen; Liming Wang; Ci Ren; Hui Shen; Wencheng Ding; Da Zhu; Lu Mao; Hui Wang
Journal:  Front Oncol       Date:  2020-11-05       Impact factor: 6.244

3.  Minimally invasive versus open surgery for women with stage 1A1 and stage 1A2 cervical cancer: A retrospective database cohort study.

Authors:  Judy Hayek; Mia Mowzoon; Saleshi Demissie; Albert Palileo; Eli Serur; Gary L Goldberg; Ioannis Alagkiozidis
Journal:  Ann Med Surg (Lond)       Date:  2022-04-07

4.  PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.

Authors:  Pinki Nandi; Gannareddy V Girish; Mousumi Majumder; Xiping Xin; Elena Tutunea-Fatan; Peeyush K Lala
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

5.  Class I hysterectomy in stage Ia2-Ib1 cervical cancer.

Authors:  Long Chen; Wei-Na Zhang; Sheng-Miao Zhang; Yuan Gao; Tian-Hong Zhang; Ping Zhang
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-06-29       Impact factor: 1.195

6.  PET/MR imaging for the evaluation of cervical cancer during pregnancy.

Authors:  Tatsuya Ishiguro; Nobumichi Nishikawa; Shiro Ishii; Kosuke Yoshihara; Kazufumi Haino; Masayuki Yamaguchi; Sosuke Adachi; Takafumi Watanabe; Shu Soeda; Takayuki Enomoto
Journal:  BMC Pregnancy Childbirth       Date:  2021-04-10       Impact factor: 3.007

7.  Cancer of the cervix uteri: 2021 update.

Authors:  Neerja Bhatla; Daisuke Aoki; Daya Nand Sharma; Rengaswamy Sankaranarayanan
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

8.  Does the New FIGO 2018 Staging System Allow Better Prognostic Differentiation in Early Stage Cervical Cancer? A Dutch Nationwide Cohort Study.

Authors:  Mieke L G Ten Eikelder; Floor Hinten; Anke Smits; Maaike A Van der Aa; Ruud L M Bekkers; Joanna IntHout; Hans H B Wenzel; Petra L M Zusterzeel
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.